{
    "organizations": [],
    "uuid": "20e7af08a92ceab8807b37fbc73ade836dd33b7a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/markets-swiss-stocks/swiss-stocks-factors-to-watch-on-april-17-idUSL8N1RT3NC",
    "ord_in_thread": 0,
    "title": "Swiss stocks - Factors to watch on April 17",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "ZURICH, April 17 (Reuters) - The Swiss blue-chip SMI was seen opening 0.6 percent higher at 8,779 points on Tuesday, according to premarket indications by bank Julius Baer .\nHere are some of the main factors that may affect Swiss stocks on Tuesday:\nSIKA The Swiss construction chemicals group reported first-quarter sales slightly above expectations on Tuesday as it awaits a court verdict in its bitter takeover battle with France’s Saint-Gobain.\nFor more news, click on\nROCHE The company’s haemophilia A drug Hemlibra will get an accelerated review by U.S. regulators for use in a new group of patients, a key part of the Swiss drug company’s plans to muscle in on turf dominated by rivals including Shire.\nFor more news, click on\nNESTLE The Swiss food group and German grocer Edeka have reached a tentative compromise in their months-long price fight and are now negotiating details of a new contract, Frankfurter Allgemeine Zeitung reported on Tuesday.\nFor more news, click on\nPOLL-Novartis Q1 sales seen up 6.2 pct\nSeparately, the company said it will invest $100 million over five years in anti-malarial drugs.\nPOLL-Sulzer Q1 orders seen up 10.6 pct The company was also maintained by MSCI in its Equity Indexes.\nCOMPANY STATEMENTS * Schmolz + Bickenbach says chairman to stand as independent\n* DKSH said its has signed a multi-product line distribution agreement for South Korea, Australia, New Zealand, Singapore and Indonesia with Bruker AXS, a provider of analytical X-ray solutions.\n* VAT Group reported a 20 percent increase in net sales during its first quarter to 198 million Swiss francs ($206.29 million).\n* Basilea said it has licensed the late-stage oncology drug candidate Derazantinib from Arqule.\n* Goldbach Group said 96.9 percent of its shares have been tendered to Tamedia.\n$1 = 0.9598 Swiss francs Reporting by Zurich newsroom\n ",
    "published": "2018-04-17T12:57:00.000+03:00",
    "crawled": "2018-04-18T18:32:16.087+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "zurich",
        "april",
        "reuters",
        "swiss",
        "smi",
        "seen",
        "opening",
        "percent",
        "higher",
        "point",
        "tuesday",
        "according",
        "premarket",
        "indication",
        "bank",
        "julius",
        "baer",
        "main",
        "factor",
        "may",
        "affect",
        "swiss",
        "stock",
        "tuesday",
        "sika",
        "swiss",
        "construction",
        "chemical",
        "group",
        "reported",
        "sale",
        "slightly",
        "expectation",
        "tuesday",
        "awaits",
        "court",
        "verdict",
        "bitter",
        "takeover",
        "battle",
        "france",
        "news",
        "click",
        "roche",
        "company",
        "haemophilia",
        "drug",
        "hemlibra",
        "get",
        "accelerated",
        "review",
        "regulator",
        "use",
        "new",
        "group",
        "patient",
        "key",
        "part",
        "swiss",
        "drug",
        "company",
        "plan",
        "muscle",
        "turf",
        "dominated",
        "rival",
        "including",
        "shire",
        "news",
        "click",
        "nestle",
        "swiss",
        "food",
        "group",
        "german",
        "grocer",
        "edeka",
        "reached",
        "tentative",
        "compromise",
        "price",
        "fight",
        "negotiating",
        "detail",
        "new",
        "contract",
        "frankfurter",
        "allgemeine",
        "zeitung",
        "reported",
        "tuesday",
        "news",
        "click",
        "q1",
        "sale",
        "seen",
        "pct",
        "separately",
        "company",
        "said",
        "invest",
        "million",
        "five",
        "year",
        "drug",
        "q1",
        "order",
        "seen",
        "pct",
        "company",
        "also",
        "maintained",
        "msci",
        "equity",
        "index",
        "company",
        "statement",
        "schmolz",
        "bickenbach",
        "say",
        "chairman",
        "stand",
        "independent",
        "dksh",
        "said",
        "signed",
        "line",
        "distribution",
        "agreement",
        "south",
        "korea",
        "australia",
        "new",
        "zealand",
        "singapore",
        "indonesia",
        "bruker",
        "ax",
        "provider",
        "analytical",
        "solution",
        "vat",
        "group",
        "reported",
        "percent",
        "increase",
        "net",
        "sale",
        "first",
        "quarter",
        "million",
        "swiss",
        "franc",
        "million",
        "basilea",
        "said",
        "licensed",
        "oncology",
        "drug",
        "candidate",
        "derazantinib",
        "arqule",
        "goldbach",
        "group",
        "said",
        "percent",
        "share",
        "tendered",
        "tamedia",
        "swiss",
        "franc",
        "reporting",
        "zurich",
        "newsroom"
    ]
}